3-<<2-(trifluoroacetamido)ethyl>amino>-1-phenoxypropan-2-ol | 53672-88-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-<<2-(trifluoroacetamido)ethyl>amino>-1-phenoxypropan-2-ol
• 英文别名: 3-[[(2-trifluoroacetamido)ethyl]amino]-1-phenoxypropan-2-ol；2,2,2-trifluoro-N-[2-[(2-hydroxy-3-phenoxypropyl)amino]ethyl]acetamide
• CAS: 53672-88-1
• 化学式: C₁₃H₁₇F₃N₂O₃
• 分子量: 306.285
• InChiKey: GNIKGZOUAVMRSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  70.6
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3--1-phenoxypropan-2-ol 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 0.5h， 生成 3-<<2-(trifluoroacetamido)ethyl>amino>-1-phenoxypropan-2-ol
  参考文献：
  名称：

  .beta.-Adrenergic blocking agents. 22. 1-Phenoxy-3-[[(substituted-amido)alkyl]amino]-2-propanols

  摘要：

  The synthesis of a series of 1-phenoxy-3-[[(substituted-amido)alkyl]amino]-2-propanols is described. Many of the compounds are more potent than propanolol as beta blockers, while having cardioselectivity comparable to that of practolol, when given intravenously to anesthetized cats. The structure-activity relationships shown by this series of compounds provide further evidence that the addition of substituents to the alkylamino moeity of a beta blocker can confer cardioselectivity and that amidic substituents are remarkably effective.

  DOI：

  10.1021/jm00353a004

文献信息

• Renin inhibitory peptides containing suleptanic acid or derivatives thereof
  申请人：THE UPJOHN COMPANY

  公开号：EP0355065A1

  公开（公告）日：1990-02-21

  The present invention provides novel renin-inhibiting peptides having a non-cleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and having a suleptanic acid moiety or derivatives thereof of the formula L₁ at the N-terminus of the peptide. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin depen­dent cardiovascular disorders and ocular disorders. Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁

  本发明提供了一种新型的抑制肾素的肽，其具有对应于肾素底物（血管紧张素原）的10,11位的不可切割过渡态插入物，并在肽的N-末端具有苏力帕尼酸基团或其衍生物的L₁式。这种抑制剂对于诊断和控制肾素依赖性高血压、充血性心力衰竭、肾素依赖性高醛固酮症、其他肾素依赖性心血管疾病和眼部疾病非常有用。Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁
• Renin inhibitors containing histidine replacements
  申请人：Merck & Co., Inc.

  公开号：EP0273696A2

  公开（公告）日：1988-07-06

  Peptides of the formula: which comprises novel elements replacing the His(9) sequence in renin-inhibitory peptides based on substrate analogy, which have improved bioavailability and pharmacodynamic properties; compositions containing these renin-inhibitory peptides, optionally with other antihypertensive agents; and methods of treating hypertension or congestive heart failure or of establishing renin as a causative factor in these problems employing the novel peptides.

  该文描述了一种新的肽类分子，其公式为：其中替代了肾素抑制肽中亮氨酸（9）序列的新元素，基于底物类比，具有改善的生物利用度和药效学特性；包含这些肾素抑制肽的组合物，可选地与其他降压药物一起使用；以及使用这些新肽治疗高血压或充血性心力衰竭或确定肾素作为这些问题的致因因素的方法。
• Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same
  申请人：Merck & Co., Inc.

  公开号：EP0129189A2

  公开（公告）日：1984-12-27

  Disclosed are renin inhibitory peptides of the formula wherein: A is, e.g., hydrogen; B is, e.g., absent; glycyl or sarcosyl; D is, e.g., absent; or -S-; E is, e.g., absent; or where F6 is, e.g., hydrogen; C1-4alkyl; or aryl; F is absent; or glycyl; R3 is, e.g., C3-6alkyl; C3-7cycloalkyl; aryl; or C3-7cycloalkyl or aryl substituted; R4 is hydrogen; where R' is hydrogen; Ci-4alkyl; hydroxy; or C3-7cycloalkyl; and R6 is as defined above; R5 is, e.g., hydrogen or where R6 and R7 are as defined above; m is 1 to 4; n is 0 to 4; and wherein all of the asymmetric carbon atoms have an S configuration, except for those in the A, B and D substituents, which may have an S or R configuration; and a pharmaceutically acceptable salt thereof. Those compounds and compositions and combinations containing the same inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.

  所公开的是式中的肾素抑制肽 其中 A 是氢； B是，例如，无；甘氨酰或肌苷； D是，例如，无；或-S-； E 是，例如，无；或 其中 F6 是，例如氢；C1-4 烷基；或芳基；F 不存在；或甘氨酰； R3 是 C3-6 烷基；C3-7 环烷基；芳基；或取代的 C3-7 环烷基或芳基； R4 是氢； 其中 R' 是氢；Ci-4烷基；羟基；或C3-7环烷基；以及 R6 如上文所定义； R5 是氢或 其中 R6 和 R7 如上定义； m 为 1 至 4 n 为 0 至 4；以及 其中除 A、B 和 D 取代基中的碳原子可具有 S 或 R 构型外，所有不对称碳原子均具有 S 构型；及其药学上可接受的盐。这些化合物和组合物以及含有相同成分的组合物能抑制肾素，可用于治疗各种形式的肾素相关性高血压和高醛固酮症。
• Renin inhibitory peptides having improved solubility
  申请人：Merck & Co., Inc.

  公开号：EP0156321A2

  公开（公告）日：1985-10-02

  Renin inhibitory peptides of the formula and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.

  式中的肾素抑制肽及其类似物可抑制肾素，用于治疗各种肾素相关性高血压和高醛固酮症。
• Renin inhibitors containing peptide isosteres
  申请人：Merck & Co., Inc.

  公开号：EP0156322A2

  公开（公告）日：1985-10-02

  Renin inhibitory peptides of the formula and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.

  式中的肾素抑制肽及其类似物可抑制肾素，用于治疗各种肾素相关性高血压和高醛固酮症。